Abbott ABT announced today
promising results from a study evaluating its High Sensitive Troponin-I
(hsTnI) assay presented at this year's American Association for Clinical
Chemistry (AACC) annual meeting in Houston, Texas. The study, conducted by
researchers at Brigham and Women's Hospital, demonstrated that Abbott's hsTnI
test (currently for research-use only in the United States) may help doctors
predict which patients presenting with symptoms of a heart attack, such as
severe chest pain, are at a higher risk for having a heart attack 30 days
later.
A concern for patients who present with severe chest pain is that they are
more likely to experience another cardiovascular event within a few weeks or
months. Researchers at Brigham and Women's Hospital evaluated the performance
of a hsTnI assay (Abbott, ARCHITECT) with the performance of a fourth
generation troponin T assay (Roche, TnT) among 4,695 patients presenting with
severe chest pain and found that the hsTnI assay identified more patients at
higher risk of recurrent heart attack, even at very low troponin
concentrations.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in